Testing high-dose methotrexate for breast cancer that has spread to the brain lining
Official title: Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests high-dose methotrexate for breast cancer that spread to the brain lining.
Read our full plain-language summary
What the trial team says
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.
Key facts
- Registry number
- NCT02422641
- Stage of testing
- Phase 2
- Conditions studied
- Metastatic Breast Cancer, Leptomeningeal Disease
Where it is running
This trial lists 3 sites.
-
Maryland
- Sidney Kimmel Comprehensive Cancer Center (Baltimore)
-
Missouri
- Siteman Cancer Center- Washington University School of Medicine in St. Louis (St Louis)
-
North Carolina
- Comprehensive Cancer Center at Wake Forest University (CCCWFU) (Winston-Salem)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.